Hummingbird Bioscience

Our Chief Executive Officer Piers Ingram is attending BioCentury Inc. East-West Biopharma Summit to discuss the upcoming innovations in Asia’s biopharma landscape. Asia CEO Roundtable 5 March 2025 11:15AM-12:30PM SGT Hummingbird Bioscience is also marking 10 years since inception—chat with Piers about the team’s journey if you will be attending. We look forward to meeting the community and catching up! #BioCenturyEastWest #biopharma

Hummingbird Bioscience will be sharing Trial-in-Progress posters for HMBD-001 at Omico’s Australian Precision Oncology Symposium (APOS) (7-8 March 2025), which will showcase the latest advancements of precision oncology in practice. Check out our posters for the latest updates on trials NCT05919537 and NCT05910827, recruiting in Australia, Singapore, and Moldova, if you are attending. Tarana Arbabzade and Rawan Dahbar, PMP are attending—chat with them to learn more.  #Omico #APOS25 #AustralianPrecisionOncologySymposium2025 #PrecisionOncology

This year’s World Cancer Day theme ‘United by Unique’ highlights how every experience with cancer is unique, and how treatment requires a people-centred approach. Meeting patients’ unique needs through precision treatment is at the heart of our work. Our ongoing partnership with Omico aims to ensure HMBD-001 reaches the right patients. HMBD-001 is currently in clinical trials in Australia, Singapore and Moldova evaluating patients with squamous cell carcinomas (NCT05910827) and patients with genetic aberrations in HER3 signaling (NCT05919537) and in the UK (NCT05057013). #UnitedbyUnique #WorldCancerDay

Press release: https://bit.ly/3BWYYAV Hummingbird Bioscience has granted Immunome, Inc. an exclusive, worldwide license to novel monoclonal antibodies that are directed to a single undisclosed target. The antibodies were generated by Hummingbird Bioscience’s proprietary epitope-focused antibody discovery platform, and we are pleased to work with Immunome, a team experienced in developing and commercializing novel ADC therapies.   #biotech #licensing #outlicensing #ADC

Press release: https://bit.ly/3BWYYAV Hummingbird Bioscience has granted Immunome, Inc. an exclusive, worldwide license to novel monoclonal antibodies that are directed to a single undisclosed target. The antibodies were generated by Hummingbird Bioscience’s proprietary epitope-focused antibody discovery platform, and we are pleased to work with Immunome, a team experienced in developing and commercializing novel ADC therapies.   #biotech #licensing #outlicensing #ADC

Jerome Boyd-Kirkup, Chief Scientific Officer at Hummingbird Bioscience, will be presenting our novel dual-payload technologies at Antibody Engineering & Therapeutics San Diego. Read more in the interview: https://bit.ly/4ioDXPY Our potentially first-in-class dual-payload ADC platform strategically combines two payloads in a manner that meaningfully potentiates cytotoxic activity in targeted cancer cells. Jerome will present the possibilities of this platform and share efficacy and safety data on HMBD-802, a HER2-targeted dual-payload ADC that could unlock new opportunities in areas of high unmet medical need.   If you will be at Antibody Engineering & Therapeutics San Diego, attend the talk to learn more. #adc #drugresistance #biotech 

The Hummingbird Bioscience team had a ball of a time at SuperBowl Mount Faber last month. The team united around the mission of leaving no pin standing, and had a great time bonding before the Deepavali festivities started. 

On 9th October 2024, Hummingbird Bioscience supported Pathlight School in facilitating the school’s visit to the National Gallery. As part of the school’s holistic education, students had the opportunity to view art exhibitions by Teo Eng Seng and Kim Lim, and explore Keppel Centre for Art Education. Hummingbird Bio had a great time with the students and we hope the experience was enriching for the students! 

Press release: https://bit.ly/3A9GSL3 Hummingbird Bioscience will present a poster presentation on HMBD-802, a novel first-in-class dual-payload anti-HER2 antibody-drug conjugate, at the 36th EORTC-NCI-AACR symposium. Poster details: Title: A novel HER2 targeted dual-payload ADC, HMBD-802, overcomes resistance to topoisomerase 1 inhibitor ADCs Date: 24 October 2024 Location: Exhibition Hall Session: Antibody-drug conjugates Poster number: PB154 Abstract number: 166   #antibodydrugconjugates #ENA2024

Angele Maki, Chief Business Officer of Hummingbird Bioscience, will be attending BIO-Europe in Stockholm, Sweden from 4-5 November. To learn more about our validated epitope-focused antibody discovery platform capabilities, please reach out to connect with Angèle. #antibodydiscovery